Anticoagulants often represent a cornerstone of therapy for patients at high risk of thrombosis. Approximately 4 million patients in the United States receive anticoagulants as primary or secondary thromboprophylaxis, a number that is expected to increase over one and a half times as guidelines shift to include more patients and indications.
Because all anticoagulants inhibit one or more clotting cofactors, unanticipated bleeding is a serious concern. Vitamin K antagonists (VKAs) may be quickly reversed with an intravenous injection of vitamin K. Until recently, the lack of a reversal agent was one of the most commonly cited disadvantages of NOACs, and was likely factor slowing their adoption into newer therapy. Fortunately, several reversal agents are in development, and one has reached the market. For those NOACs that do not yet have approved antidotes, nonpharmacologic reversal techniques do exist, and supportive care becomes a priority.
Introduction to NOACs [Objective 1]
Anticoagulant reversal [Objectives 2 & 3]
New and emerging anticoagulant reversal agents [Objectives 3 & 4]
Summary, best practice recap, conclusion
The following healthcare professionals: cardiologists, trauma surgeons, emergency medicine specialists, intensivists, internists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in anticoagulation, emergency medicine, or critical care; and any other healthcare professionals who clinically encounter patients taking NOACs.
This program is supported by an educational grant from Portola Pharmaceuticals
Release Date: October 15, 2017 -- Expiration Date: October 15, 2019
Faculty: Diane Birnbaumer, MD
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Diane Birnbaumer, MD, FACEP, Emeritus Professor of Medicine University of California, Los Angeles, Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA Medical Center has served as a consultant to Securisyn.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Portola Pharmaceuticals
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.